Publicaties
| 1. | UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.
Peeters, S.L., Deenen, M.J., Thijs, A.M., Hulshof, E.C., Mathijssen, R.H., Gelderblom, H,. Guchelaar, H.J., Swen, J.J. Pharmacogenomics. 2023 Jun;24(8):435-439. https://doi.org/10.2217/pgs-2023-0096. |
| 2. | The Effect of Genotyping on the Number of Pharmacotherapeutic Gene-Drug Interventions in Chronic Kidney Disease Patients.
Kerskes, C.H.M., van den Eijnde, C.J.M.E., Aarnoudse, A.L.H.J., Grouls, R.J.E., Deiman, B.A.L.M., Deenen, M.J. Pharmacy (Basel). 2023 Apr 4;11(2):69. https://doi.org/10.3390/pharmacy11020069. |
| 3. | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer.
Kicken, M.P., Kilinc, H.D., Cramer-van der Welle, C.M., Houterman, S., van den Borne, B.E.E.M., Smit, A.A.J., van de Garde, E.M.W., Deenen, M.J.; Santeon NSCLC study group. Cancer Treat Res Commun. 2023;34:100676. https://doi.org/10.1016/j.ctarc.2022.100676. |
| 4. | Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.
van den Wildenberg, S.A.H., Streng, A.S., van den Broek, R., Broeren, M.A.C., Deenen, M.J., van Dongen, J..LJ., Hanrath, M.A., Lapré, C., Brunsveld, L., Scharnhorst, V., van de Kerkhof, D. J Pharm Biomed Anal. 2022 Nov 30;221:115027. https://doi.org/10.1016/j.jpba.2022.115027. |
| 5. | UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof, E.C., de With, M., de Man, F.M., Creemers, G.J., Deiman, B.A.L.M., Swen, J.J., Houterman, S., Koolen, S.L.W., Bins, S., Thijs, A.M.J., Laven, M.M.J., Hövels, A.M., Luelmo, S.A.C., Houtsma, D., Shulman, K., McLeod, H.L., van Schaik, R.H.N., Guchelaar, H.J., Mathijssen, R.H.J., Gelderblom, H., Deenen, M.J. Eur J Cancer. 2022 Feb;162:148-157. https://doi.org/10.1016/j.ejca.2021.12.009. |
| 6. | Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.
Hulshof, E.C., Lim, L., de Hingh, I.H.J.T., Gelderblom, H., Guchelaar, H.J., Deenen, M.J.. Front Pharmacol. 2020 Oct 6;11:577968. https://doi.org/10.3389/fphar.2020.577968. |
| 7. | Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial.
Lurvink, R.J., Tajzai, R., Rovers, K.P., Wassenaar, E.C.E., Moes, D.A.R., Pluimakers, G., Boerma, D., Burger, J.W.A., Nienhuijs, S.W., de Hingh, I.H.J.T., Deenen, M.J. Ann Surg Oncol. 2021 Jan;28(1):265-272. https://doi.org/10.1245/s10434-020-08743-9. |
| 8. | Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Hulshof, E.C., Lurvink, R.J., Caserta, N., de Hingh, I.H.J.T, van Wezel, T., Böhringer, S., Swen, J.J., Gelderblom, H., Guchelaar, H.J., Deenen, M.J. Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1925-1931. https://doi.org/10.1016/j.ejso.2020.04.019. |
| 9. | The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.
Poulussen, F.C.P., Peters, B.J., Hua, K.H., Houthuizen, P., Grouls, R.J., Deenen, M.J. Pharmacogenet Genomics. 2019 Sep;29(7):179-182. https://doi.org/10.1097/FPC.0000000000000381. |
| 10. | The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.
Bury, D., Ter Heine, R., van de Garde, E.M.W., Nijziel, M.R., Grouls, R.J., Deenen, M.J. Eur J Clin Pharmacol. 2019 Jul;75(7):921-928. https://doi.org/10.1007/s00228-019-02657-6. |
| 11. | Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.
de Jong, C., Sanders, S., Creemers, G.J., Burylo, A.M., Taks, M., Schellens, J.H.M., Deenen, M.J. Br J Clin Pharmacol. 2017 Sep;83(9):2120-2122. https://doi.org/10.1111/bcp.13309. |